Abstracts tagged "longitudinal studies"

Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Mark Siderius¹, Freke Wink¹, Anneke Spoorenberg¹ and Suzanne Arends¹, ¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
Abstract Number: 0272 • ACR Convergence 2020
Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
Eric Morand¹, Vera Golder², Worawit Louthrenoo³, Shue Fen Luo⁴, Yeong-Jian Wu⁵, Aisha Lateef⁶, Sargunan Sockalingam⁷, Sandra Navarra⁸, Leonid Zamora⁹, Laniyati Hamijoyo¹⁰, Yasuhiro Katsumata¹¹, Masayoshi Harigai¹², Madelynn Chan¹³, Sean O'Neill¹⁴, Fiona Goldblatt¹⁵, Yi-Hsing Chen¹⁶, Yanjie Hao¹⁷, Zhuoli Zhang¹⁷, Jun Kikuchi¹⁸, Tsutomu Takeuchi¹⁹, Chak Sing Lau²⁰, Zhanguo Li²¹, Alberta Hoi²², Mandana Nikpour²³ and Rangi Kandane-Rathnayake², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²Monash University, Clayton, Victoria, Australia, ³Chiang Mai University Hospital, Muang, Thailand, ⁴Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Thomas, Manila, Philippines, ¹⁰University of Padjadjaran, Bandung, Indonesia, ¹¹Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴Sydney University, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹⁷Peking University First Hospital, Beijing, China (People's Republic), ¹⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁹Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ²⁰Hong Kong University, Hong Kong, Hong Kong, ²¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), ²²Monash University, Melbourne, Victoria, Australia, ²³The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia
Background/Purpose: Treat-to-target (T2T) approaches to rheumatic disease require the definition and validation of low disease activity and remission endpoints that should be concentrically more stringent.…
Abstract Number: 1451 • ACR Convergence 2020
Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE
Michelle Petri¹, Laurence Magder² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Although anti-beta2 glycoprotein is one of the three antiphospholipid antibodies recognized in the Sydney APS classification criteria, it is one of the least studied. …
Abstract Number: 0302 • ACR Convergence 2020
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Kieran Manion¹, Dennisse Bonilla², Dafna Gladman¹, Murray Urowitz³, Zahi Touma⁴ and Joan Wither², ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
Abstract Number: 1467 • ACR Convergence 2020
Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
Andre Luquini¹, Yufei Zheng², Hui Xie³, Catherine Backman¹, Pamela Rogers³, Alex Kwok³, Astrid Knight³, Monique Gignac⁴, Dianne Mosher⁵, Linda Li¹, John Esdaile⁶, Carter Thorne⁷ and Diane Lacaille¹, ¹University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, ²Simon Fraser University / Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Institute for Work & Health / University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Arthritis Research Canada, Vancouver, BC, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: Arthritis often leads to presenteeism (decreased at-work productivity) and permanent work disability, the worst occupational outcome of a disease, leading to reduced quality of…
Abstract Number: 0307 • ACR Convergence 2020
Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis
Alexis Ogdie¹, Martin Rozycki², Theresa Arndt², Cheng Shi³, Nina Kim⁴ and Peter Hur³, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴The University of Texas at Austin; Baylor Scott and White Health, Austin, TX
Background/Purpose: In developing algorithms within claims databases that may inform how to find patients with psoriatic arthritis (PsA) prior to diagnosis, it is important to…
Abstract Number: 1471 • ACR Convergence 2020
Healthy Lifestyle and Risk of Rheumatoid Arthritis in Women: A Prospective Cohort Study
Jill Hahn¹, May Choi², Susan Malspeis³, Emma Stevens⁴, Elizabeth Karlson⁴, Kazuki Yoshida⁵, Laura Kubzansky⁶, Jeffrey Sparks⁷ and Karen Costenbader⁸, ¹Brigham and Womens' Hospital, Newton, MA, ²Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Harvard T.H. Chan School of Public Health, Boston, MA, ⁷Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Many potentially modifiable biobehavioral factors have been associated with the risk of developing rheumatoid arthritis (RA), but the benefit of adopting an overall healthy…
Abstract Number: 0542 • ACR Convergence 2020
Examining the Long-Term and Short-Term Day-To-Day Pain Variability in Inflammatory and Non-Inflammatory Rheumatic and Musculoskeletal Diseases Using Multilevel and Markov Transition Models: Cloudy with a Chance of Pain, a National U.K. Smartphone Study
Huai Leng Pisaniello¹, Mark Lunt², John McBeth³ and William Dixon², ¹University of Adelaide, Kidman Park, South Australia, Australia, ²Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, ³University of Manchester, Manchester, United Kingdom
Background/Purpose: Chronic pain is common in rheumatic and musculoskeletal diseases (RMDs), yet the patterns and the extent of variability over time are poorly understood. Real-time…
Abstract Number: 1493 • ACR Convergence 2020
Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis
Stephanie Shoop-Worrall¹, Kimme Hyrich², Lucy Wedderburn³, Wendy Thomson⁴ and Nophar Geifman⁵, ¹Centre for Health Informatics, Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³UCL, UCLH, GOS Institute of Child Health, London, United Kingdom, ⁴Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Centre for Health Informatics, The University of Manchester, Manchester
Background/Purpose: Treatment response in JIA is often viewed as a binary outcome: response or non-response, usually assessed using composite, multidimensional measures, such as the juvenile…
Abstract Number: 0672 • ACR Convergence 2020
Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares
Natalie McCormick¹, Chio Yokose¹, Clara Chen², Tuhina Neogi³, David Hunter⁴, Hyon Choi⁵ and Yuqing Zhang⁶, ¹Massachusetts General Hospital, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston
Background/Purpose: Cross-sectional radiologic evidence suggests monosodium urate crystal deposition among gout patients is a symmetrical phenomenon,1 but no study has examined the longitudinal patterns in…
Abstract Number: 1512 • ACR Convergence 2020
Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis
Andrea Fava¹, Avi Rosenberg², Serena Bagnasco², Paride Fenaroli², Jessica Li¹, Jose Monroy-Trujillo², Derek Fine² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…
Abstract Number: 120 • 2020 Pediatric Rheumatology Symposium
Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years
Jessica Neely¹, Adam Huber ² and Susan Kim ³ for the CARRA investigators, ¹University of California, San Francisco, San Francisco, California, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³University of California, San Francisco, San Francisco
Background/Purpose: The New CARRA Registry of Juvenile Myositis (JM) was developed in 2017 to collect 10-year longitudinal data to increase knowledge of the course of…
Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Mia Glerup¹, Ellen D Arnstad ², Veronika Rypdal ³, Suvi Peltoniemi ⁴, Kristiina Aalto ⁵, Marite Rygg ⁶, Susan Nielsen ⁷, Anders Fasth ⁸, Lillemor Berntson ⁹, Ellen Nordal ³ and Troels Herlin ¹⁰, ¹Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, ³Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ⁴Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, ⁵Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁶Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, ⁸Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
Abstract Number: 188 • 2019 ACR/ARP Annual Meeting
The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood
Kristin Wipfler¹, Sofia Pedro ¹, Yomei Shaw ¹, Rebecca Schumacher ¹, Teresa Simon ², Alyssa Dominique ³, Adam Reinhardt ⁴ and Kaleb Michaud ⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb*, Princeton, NJ, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Children’s Hospital & Medical Center & University of Nebraska Medical Center, Omaha, NE, ⁵FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Upon transitioning from pediatric to adult care, many patients with JIA are labeled as having RA, despite the two diagnoses being distinct in care…
Abstract Number: 604 • 2019 ACR/ARP Annual Meeting
Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort
Miranda van Lunteren¹, Robert B.M. Landewé ², Camilla Fongen ³, Roberta Ramonda ⁴, Désirée van der Heijde ¹ and Floris van Gaalen ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University of Padova, Padova, Italy
Background/Purpose: We have previously shown that in patients with recently diagnosed axial SpA (axSpA), illness perceptions had a negative impact on the relationship between back…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].